These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29110755)

  • 21. Nephropathy Progression in African Americans With a Family History of ESKD: Implications for Clinical Trials in APOL1-Associated Nephropathy.
    Freedman BI; Spainhour M; Hicks PJ; Turner J; Robertson J; Langefeld CD; Murea M; Divers J
    Am J Kidney Dis; 2019 Aug; 74(2):284-286. PubMed ID: 31076172
    [No Abstract]   [Full Text] [Related]  

  • 22. Survival Advantage of African American Dialysis Patients with End-Stage Renal Disease Causes Related to APOL1.
    Lertdumrongluk P; Streja E; Rhee CM; Moradi H; Chang Y; Reddy U; Tantisattamo E; Kalantar-Zadeh K; Kopp JB
    Cardiorenal Med; 2019; 9(4):212-221. PubMed ID: 30995638
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.
    Li D; Snipes JA; Murea M; Molina AJA; Divers J; Freedman BI; Ma L; Petrovic S
    Am J Nephrol; 2020; 51(9):695-704. PubMed ID: 32866949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Expanding Role of APOL1 Risk in Chronic Kidney Disease and Cardiovascular Disease.
    Estrella MM; Parekh RS
    Semin Nephrol; 2017 Nov; 37(6):520-529. PubMed ID: 29110759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. APOL1 risk variants and kidney disease: what we know so far.
    Siemens TA; Riella MC; Moraes TP; Riella CV
    J Bras Nefrol; 2018; 40(4):388-402. PubMed ID: 30052698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. APOL1-Mediated Kidney Disease.
    Hopper T; Olabisi OA
    JAMA; 2024 May; 331(19):1668-1669. PubMed ID: 38662391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of
    Paranjpe I; Chaudhary K; Paranjpe M; O'Hagan R; Manna S; Jaladanki S; Kapoor A; Horowitz C; DeFelice N; Cooper R; Glicksberg B; Bottinger EP; Just AC; Nadkarni GN
    Clin J Am Soc Nephrol; 2020 Mar; 15(3):401-403. PubMed ID: 32079610
    [No Abstract]   [Full Text] [Related]  

  • 28. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
    Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
    Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
    [TBL] [Abstract][Full Text] [Related]  

  • 29. APOL1, Black Race, and Kidney Disease: Turning Attention to Structural Racism.
    Cerdeña JP; Tsai J; Grubbs V
    Am J Kidney Dis; 2021 Jun; 77(6):857-860. PubMed ID: 33485919
    [No Abstract]   [Full Text] [Related]  

  • 30. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy.
    Papeta N; Kiryluk K; Patel A; Sterken R; Kacak N; Snyder HJ; Imus PH; Mhatre AN; Lawani AK; Julian BA; Wyatt RJ; Novak J; Wyatt CM; Ross MJ; Winston JA; Klotman ME; Cohen DJ; Appel GB; D'Agati VD; Klotman PE; Gharavi AG
    J Am Soc Nephrol; 2011 Nov; 22(11):1991-6. PubMed ID: 21997397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. APOL1 risk variants, race, and progression of chronic kidney disease.
    Parsa A; Kao WH; Xie D; Astor BC; Li M; Hsu CY; Feldman HI; Parekh RS; Kusek JW; Greene TH; Fink JC; Anderson AH; Choi MJ; Wright JT; Lash JP; Freedman BI; Ojo A; Winkler CA; Raj DS; Kopp JB; He J; Jensvold NG; Tao K; Lipkowitz MS; Appel LJ; ;
    N Engl J Med; 2013 Dec; 369(23):2183-96. PubMed ID: 24206458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOL1 G2 risk allele-clarifying nomenclature.
    Zhang Z; Hao K; Ross MJ; Murphy B; Menon MC
    Kidney Int; 2017 Aug; 92(2):518-519. PubMed ID: 28709608
    [No Abstract]   [Full Text] [Related]  

  • 33. APOL1 risk variants and the development of HIV-associated nephropathy.
    Goyal R; Singhal PC
    FEBS J; 2021 Oct; 288(19):5586-5597. PubMed ID: 33340240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cases in Precision Medicine: APOL1 and Genetic Testing in the Evaluation of Chronic Kidney Disease and Potential Transplant.
    Neugut YD; Mohan S; Gharavi AG; Kiryluk K
    Ann Intern Med; 2019 Nov; 171(9):659-664. PubMed ID: 31590185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recurrent Focal Segmental Glomerulosclerosis After Kidney Transplantation in African Americans: Review of the Current Evidence.
    Theophilus UI; John JR; Ihab S; Ahmed H
    Exp Clin Transplant; 2021 Dec; 19(12):1245-1256. PubMed ID: 34269655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetics and ESKD Disparities in African Americans.
    Umeukeje EM; Young BA
    Am J Kidney Dis; 2019 Dec; 74(6):811-821. PubMed ID: 31606237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of Injury in APOL1-associated Kidney Disease.
    Ma L; Divers J; Freedman BI
    Transplantation; 2019 Mar; 103(3):487-492. PubMed ID: 30371607
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apolipoprotein L1 Gene Effects on Kidney Transplantation.
    Freedman BI; Locke JE; Reeves-Daniel AM; Julian BA
    Semin Nephrol; 2017 Nov; 37(6):530-537. PubMed ID: 29110760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics. Kidney disease is parasite-slaying protein's downside.
    Leslie M
    Science; 2010 Jul; 329(5989):263. PubMed ID: 20647431
    [No Abstract]   [Full Text] [Related]  

  • 40. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.
    Reidy KJ; Hjorten R; Parekh RS
    Curr Opin Pediatr; 2018 Apr; 30(2):252-259. PubMed ID: 29406442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.